Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression
Authors:
- 1 April 2015
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 359 (1) , 127-135
Abstract
No abstract availableKeywords
Funding Information
- The Science & Technology Project in Guangzhou City-Zhujiang Science & Technology New Star (2012J2200039)
This publication has 28 references indexed in Scilit:
- PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in miceBritish Journal of Cancer, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Hematoporphyrin derivative‐mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivoHepatology Research, 2009
- Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathwayActa Pharmacologica Sinica, 2009
- Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cellsActa Pharmacologica Sinica, 2007
- The Many Faces of PPARγCell, 2005
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004
- Peroxisome-proliferator-activated receptors and cancers: complex storiesNature Reviews Cancer, 2004
- Selective activation of PPARγ inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activatorSurgery, 2003
- PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisJournal of Clinical Investigation, 2002